By negatively regulating TNF-α, AZGP1 reduces the severity of Nonalcoholic fatty liver disease (NAFLD) by lowering inflammation, speeding lipolysis, boosting proliferation, and minimizing apoptosis. This evidence concerns the gene TNF and metabolic dysfunction-associated steatotic liver disease.